| Name | Title | Contact Details |
|---|
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Vi-Jon aims to offer our own branded products in particular specialized markets. Vi-Jon is proud to produce Germ-X, a leader among waterless antibacterial hand sanitizers.
Hallman Group is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
North Okaloosa Medical Center is a Crestview, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OptimizeRx® (OPRX) provides unique physician and consumer platforms and strategies to help patients better afford and adhere to their treatment regimens, while offering pharmaceutical and healthcare companies more effective ways to deliver relevant information and services to healthcare providers and their patients right at the point of care.